Melanie Everitt
Concepts (312)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 60 | 2025 | 754 | 9.880 |
Why?
| | Graft Rejection | 25 | 2025 | 624 | 4.200 |
Why?
| | Heart Defects, Congenital | 14 | 2023 | 842 | 2.340 |
Why?
| | Cardiomyopathies | 11 | 2024 | 350 | 2.180 |
Why?
| | Waiting Lists | 12 | 2024 | 266 | 1.480 |
Why?
| | Registries | 17 | 2024 | 2035 | 1.410 |
Why?
| | Cardiomyopathy, Dilated | 8 | 2024 | 385 | 1.370 |
Why?
| | Fontan Procedure | 5 | 2023 | 180 | 1.030 |
Why?
| | Antibodies | 8 | 2022 | 410 | 1.000 |
Why?
| | Heart Diseases | 6 | 2019 | 346 | 0.990 |
Why?
| | Heart Failure | 14 | 2024 | 2236 | 0.950 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2021 | 301 | 0.940 |
Why?
| | Survival Rate | 19 | 2024 | 1972 | 0.930 |
Why?
| | Child | 56 | 2025 | 21935 | 0.910 |
Why?
| | Heart-Assist Devices | 9 | 2024 | 552 | 0.880 |
Why?
| | Postoperative Complications | 12 | 2025 | 2654 | 0.870 |
Why?
| | Donor Selection | 3 | 2020 | 77 | 0.840 |
Why?
| | Graft Survival | 9 | 2025 | 535 | 0.820 |
Why?
| | Ventricular Dysfunction | 2 | 2013 | 15 | 0.800 |
Why?
| | Child, Preschool | 36 | 2025 | 11074 | 0.790 |
Why?
| | Tissue Donors | 5 | 2020 | 425 | 0.750 |
Why?
| | Heterotaxy Syndrome | 1 | 2021 | 14 | 0.720 |
Why?
| | Retrospective Studies | 34 | 2025 | 15657 | 0.720 |
Why?
| | Neurodevelopmental Disorders | 2 | 2024 | 181 | 0.710 |
Why?
| | Follow-Up Studies | 19 | 2024 | 5131 | 0.670 |
Why?
| | Marfan Syndrome | 2 | 2011 | 41 | 0.670 |
Why?
| | Immunosuppressive Agents | 6 | 2025 | 890 | 0.660 |
Why?
| | Societies, Medical | 3 | 2024 | 820 | 0.640 |
Why?
| | Infant | 29 | 2025 | 9465 | 0.630 |
Why?
| | General Practice | 1 | 2019 | 29 | 0.620 |
Why?
| | Adolescent | 39 | 2025 | 21513 | 0.610 |
Why?
| | Coronary Vessels | 2 | 2018 | 248 | 0.600 |
Why?
| | Primary Graft Dysfunction | 1 | 2019 | 32 | 0.600 |
Why?
| | Aortic Aneurysm, Thoracic | 2 | 2011 | 131 | 0.600 |
Why?
| | Medication Adherence | 2 | 2019 | 467 | 0.580 |
Why?
| | Myocardium | 9 | 2023 | 1002 | 0.580 |
Why?
| | Biopsy | 9 | 2024 | 1129 | 0.570 |
Why?
| | Humans | 90 | 2025 | 137585 | 0.550 |
Why?
| | Patient Selection | 3 | 2024 | 696 | 0.550 |
Why?
| | Blood Group Incompatibility | 2 | 2024 | 15 | 0.550 |
Why?
| | ABO Blood-Group System | 2 | 2024 | 51 | 0.530 |
Why?
| | Ventricular Dysfunction, Left | 4 | 2024 | 382 | 0.520 |
Why?
| | Male | 60 | 2025 | 67762 | 0.510 |
Why?
| | Risk Factors | 17 | 2024 | 10388 | 0.510 |
Why?
| | Echocardiography, Doppler | 2 | 2024 | 108 | 0.460 |
Why?
| | Female | 58 | 2025 | 73304 | 0.460 |
Why?
| | Ventricular Remodeling | 3 | 2024 | 266 | 0.440 |
Why?
| | Cardiomyopathy, Hypertrophic | 4 | 2023 | 142 | 0.420 |
Why?
| | Tacrolimus | 2 | 2025 | 199 | 0.420 |
Why?
| | Tissue and Organ Procurement | 5 | 2022 | 321 | 0.420 |
Why?
| | Coronary Artery Disease | 2 | 2024 | 698 | 0.420 |
Why?
| | Hemodynamics | 4 | 2022 | 1113 | 0.390 |
Why?
| | Transplant Recipients | 2 | 2025 | 184 | 0.390 |
Why?
| | Genetic Testing | 4 | 2024 | 460 | 0.390 |
Why?
| | Arrhythmias, Cardiac | 3 | 2013 | 333 | 0.380 |
Why?
| | Vascular Remodeling | 1 | 2014 | 193 | 0.380 |
Why?
| | Death, Sudden, Cardiac | 2 | 2012 | 185 | 0.380 |
Why?
| | Aneurysm | 1 | 2011 | 31 | 0.370 |
Why?
| | Treatment Outcome | 16 | 2025 | 10811 | 0.360 |
Why?
| | American Heart Association | 3 | 2019 | 306 | 0.360 |
Why?
| | Protein-Losing Enteropathies | 1 | 2011 | 10 | 0.350 |
Why?
| | Electrocardiography | 2 | 2014 | 629 | 0.350 |
Why?
| | Organ Transplantation | 2 | 2024 | 250 | 0.340 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2011 | 58 | 0.330 |
Why?
| | Aortic Valve | 2 | 2014 | 351 | 0.330 |
Why?
| | Defibrillators | 1 | 2010 | 16 | 0.330 |
Why?
| | Ventricular Fibrillation | 1 | 2010 | 60 | 0.320 |
Why?
| | Incidence | 7 | 2025 | 2804 | 0.300 |
Why?
| | Kidney Diseases | 2 | 2023 | 408 | 0.300 |
Why?
| | Ventricular Function, Left | 3 | 2024 | 534 | 0.300 |
Why?
| | Craniofacial Abnormalities | 1 | 2009 | 72 | 0.300 |
Why?
| | Mitral Valve | 1 | 2009 | 88 | 0.300 |
Why?
| | Infant, Newborn | 12 | 2024 | 6079 | 0.290 |
Why?
| | Tachycardia, Ventricular | 1 | 2010 | 175 | 0.290 |
Why?
| | Kidney Transplantation | 3 | 2023 | 708 | 0.280 |
Why?
| | Heart Ventricles | 4 | 2017 | 788 | 0.280 |
Why?
| | Predictive Value of Tests | 4 | 2024 | 2031 | 0.270 |
Why?
| | Severity of Illness Index | 6 | 2018 | 2828 | 0.270 |
Why?
| | Prognosis | 9 | 2024 | 4030 | 0.260 |
Why?
| | Allografts | 2 | 2024 | 146 | 0.260 |
Why?
| | Aorta, Thoracic | 1 | 2009 | 267 | 0.260 |
Why?
| | Glomerular Filtration Rate | 3 | 2024 | 746 | 0.250 |
Why?
| | Perioperative Care | 2 | 2017 | 178 | 0.240 |
Why?
| | Everolimus | 1 | 2025 | 91 | 0.240 |
Why?
| | Palliative Care | 1 | 2012 | 758 | 0.230 |
Why?
| | Mycophenolic Acid | 1 | 2025 | 117 | 0.230 |
Why?
| | Peripheral Arterial Disease | 1 | 2011 | 475 | 0.230 |
Why?
| | Transplants | 2 | 2022 | 36 | 0.230 |
Why?
| | Young Adult | 15 | 2024 | 13209 | 0.230 |
Why?
| | Time Factors | 7 | 2024 | 6828 | 0.220 |
Why?
| | Risk Assessment | 4 | 2023 | 3457 | 0.220 |
Why?
| | Vascular Resistance | 3 | 2014 | 375 | 0.220 |
Why?
| | Adult | 24 | 2024 | 37929 | 0.220 |
Why?
| | Databases, Factual | 1 | 2009 | 1357 | 0.210 |
Why?
| | Genetic Counseling | 1 | 2024 | 77 | 0.210 |
Why?
| | Delayed-Action Preparations | 1 | 2024 | 181 | 0.210 |
Why?
| | Heart | 3 | 2023 | 655 | 0.210 |
Why?
| | Transplantation, Homologous | 3 | 2021 | 416 | 0.200 |
Why?
| | Bacterial Infections | 1 | 2025 | 250 | 0.200 |
Why?
| | Contrast Media | 2 | 2023 | 467 | 0.190 |
Why?
| | Practice Patterns, Physicians' | 2 | 2024 | 1313 | 0.190 |
Why?
| | Inheritance Patterns | 1 | 2022 | 45 | 0.190 |
Why?
| | Hypoplastic Left Heart Syndrome | 2 | 2014 | 121 | 0.190 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2025 | 617 | 0.180 |
Why?
| | Magnetic Resonance Imaging, Cine | 3 | 2023 | 193 | 0.180 |
Why?
| | Echocardiography | 6 | 2018 | 642 | 0.180 |
Why?
| | Exome | 1 | 2022 | 231 | 0.170 |
Why?
| | Prospective Studies | 7 | 2023 | 7604 | 0.170 |
Why?
| | Phenotype | 4 | 2022 | 3196 | 0.160 |
Why?
| | Clinical Decision-Making | 1 | 2022 | 322 | 0.160 |
Why?
| | Genetic Predisposition to Disease | 4 | 2022 | 2426 | 0.160 |
Why?
| | Respiratory Insufficiency | 1 | 2023 | 318 | 0.160 |
Why?
| | Noonan Syndrome | 1 | 2019 | 17 | 0.160 |
Why?
| | Pneumonia | 1 | 2025 | 639 | 0.150 |
Why?
| | United States | 14 | 2024 | 14841 | 0.150 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2023 | 413 | 0.150 |
Why?
| | Neuropsychological Tests | 2 | 2021 | 1023 | 0.150 |
Why?
| | Proportional Hazards Models | 7 | 2017 | 1266 | 0.150 |
Why?
| | Hyperplasia | 1 | 2018 | 175 | 0.140 |
Why?
| | Child Nutrition Disorders | 1 | 2018 | 20 | 0.140 |
Why?
| | Global Health | 1 | 2021 | 386 | 0.140 |
Why?
| | Surgical Wound Dehiscence | 1 | 2017 | 22 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 2 | 2017 | 889 | 0.140 |
Why?
| | Survival Analysis | 4 | 2021 | 1325 | 0.140 |
Why?
| | Cohort Studies | 6 | 2022 | 5742 | 0.140 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 570 | 0.140 |
Why?
| | Cognition Disorders | 1 | 2021 | 496 | 0.130 |
Why?
| | Death | 1 | 2017 | 119 | 0.130 |
Why?
| | Age Factors | 3 | 2024 | 3295 | 0.130 |
Why?
| | Genotype | 1 | 2022 | 1916 | 0.130 |
Why?
| | Extracorporeal Circulation | 1 | 2016 | 13 | 0.130 |
Why?
| | Executive Function | 1 | 2021 | 451 | 0.120 |
Why?
| | Myocardial Contraction | 2 | 2024 | 341 | 0.120 |
Why?
| | Sirolimus | 1 | 2017 | 276 | 0.120 |
Why?
| | Isolated Noncompaction of the Ventricular Myocardium | 1 | 2015 | 4 | 0.120 |
Why?
| | Cardio-Renal Syndrome | 1 | 2015 | 12 | 0.120 |
Why?
| | Genes, Neurofibromatosis 1 | 1 | 2015 | 4 | 0.120 |
Why?
| | Pseudarthrosis | 1 | 2015 | 12 | 0.120 |
Why?
| | Cardiology | 1 | 2017 | 274 | 0.110 |
Why?
| | Fluorescent Antibody Technique | 1 | 2015 | 390 | 0.110 |
Why?
| | Neurofibromatosis 1 | 1 | 2015 | 52 | 0.110 |
Why?
| | Surgical Wound Infection | 1 | 2017 | 307 | 0.110 |
Why?
| | Tachycardia | 1 | 2014 | 57 | 0.110 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2014 | 69 | 0.110 |
Why?
| | Referral and Consultation | 1 | 2019 | 786 | 0.110 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 508 | 0.110 |
Why?
| | Sequence Deletion | 1 | 2014 | 183 | 0.100 |
Why?
| | Cardiovascular Diseases | 3 | 2012 | 2111 | 0.100 |
Why?
| | T-Box Domain Proteins | 1 | 2014 | 98 | 0.100 |
Why?
| | Pediatrics | 3 | 2016 | 1101 | 0.100 |
Why?
| | Tibia | 1 | 2015 | 178 | 0.100 |
Why?
| | Arterial Pressure | 1 | 2014 | 126 | 0.100 |
Why?
| | Age Distribution | 1 | 2014 | 392 | 0.100 |
Why?
| | Sex Distribution | 1 | 2014 | 375 | 0.100 |
Why?
| | Reoperation | 2 | 2021 | 573 | 0.100 |
Why?
| | Cardiomyopathy, Restrictive | 1 | 2012 | 10 | 0.100 |
Why?
| | Gene Expression Regulation | 1 | 2022 | 2607 | 0.100 |
Why?
| | Abnormalities, Multiple | 1 | 2014 | 189 | 0.100 |
Why?
| | Middle Aged | 13 | 2017 | 33479 | 0.090 |
Why?
| | Anxiety | 1 | 2019 | 1035 | 0.090 |
Why?
| | Immunoglobulins | 1 | 2012 | 171 | 0.090 |
Why?
| | International Cooperation | 1 | 2012 | 198 | 0.090 |
Why?
| | Liver Diseases | 1 | 2014 | 315 | 0.090 |
Why?
| | Capillaries | 1 | 2012 | 108 | 0.090 |
Why?
| | Glucaric Acid | 1 | 2011 | 4 | 0.090 |
Why?
| | Fibrosis | 3 | 2023 | 552 | 0.090 |
Why?
| | Altitude Sickness | 1 | 2013 | 153 | 0.090 |
Why?
| | Tissue and Organ Harvesting | 1 | 2011 | 70 | 0.090 |
Why?
| | Hematinics | 1 | 2011 | 22 | 0.090 |
Why?
| | Cardiotonic Agents | 1 | 2011 | 124 | 0.090 |
Why?
| | Treatment Failure | 1 | 2012 | 356 | 0.090 |
Why?
| | Stroke Volume | 1 | 2014 | 612 | 0.090 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2011 | 131 | 0.090 |
Why?
| | Ferric Compounds | 1 | 2011 | 56 | 0.090 |
Why?
| | Healthcare Disparities | 1 | 2017 | 654 | 0.080 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2010 | 37 | 0.080 |
Why?
| | Diverticulum | 1 | 2010 | 12 | 0.080 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2010 | 36 | 0.080 |
Why?
| | Pediatric Obesity | 1 | 2018 | 601 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2017 | 951 | 0.080 |
Why?
| | Kidney Function Tests | 2 | 2024 | 160 | 0.080 |
Why?
| | Carbazoles | 1 | 2010 | 83 | 0.080 |
Why?
| | Disease Management | 1 | 2014 | 628 | 0.080 |
Why?
| | Propanolamines | 1 | 2010 | 96 | 0.080 |
Why?
| | Blood Component Transfusion | 1 | 2010 | 84 | 0.080 |
Why?
| | Recovery of Function | 1 | 2014 | 653 | 0.080 |
Why?
| | Magnetic Resonance Angiography | 1 | 2011 | 240 | 0.080 |
Why?
| | Negative-Pressure Wound Therapy | 1 | 2009 | 27 | 0.080 |
Why?
| | Heart-Lung Transplantation | 2 | 2024 | 14 | 0.080 |
Why?
| | Mutation | 3 | 2019 | 3958 | 0.080 |
Why?
| | Resource Allocation | 1 | 2009 | 52 | 0.080 |
Why?
| | Dopamine | 1 | 2011 | 303 | 0.070 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 5472 | 0.070 |
Why?
| | Syndrome | 1 | 2009 | 358 | 0.070 |
Why?
| | Pulmonary Artery | 1 | 2014 | 1086 | 0.070 |
Why?
| | Immune Tolerance | 1 | 2010 | 363 | 0.070 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1509 | 0.070 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2009 | 180 | 0.070 |
Why?
| | Defibrillators, Implantable | 1 | 2010 | 315 | 0.070 |
Why?
| | Connexin 43 | 1 | 2007 | 32 | 0.070 |
Why?
| | Risk | 1 | 2010 | 912 | 0.070 |
Why?
| | Wound Healing | 1 | 2009 | 331 | 0.070 |
Why?
| | Arrhythmogenic Right Ventricular Dysplasia | 1 | 2007 | 57 | 0.070 |
Why?
| | Health Care Surveys | 2 | 2020 | 565 | 0.060 |
Why?
| | Morbidity | 2 | 2021 | 324 | 0.060 |
Why?
| | Health Policy | 1 | 2009 | 388 | 0.060 |
Why?
| | Patient Compliance | 1 | 2010 | 581 | 0.060 |
Why?
| | Cadherins | 1 | 2007 | 206 | 0.060 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 5778 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2025 | 2057 | 0.060 |
Why?
| | Lymphoproliferative Disorders | 1 | 2025 | 57 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2691 | 0.060 |
Why?
| | Biomarkers | 4 | 2023 | 4149 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1587 | 0.060 |
Why?
| | Canada | 2 | 2017 | 418 | 0.060 |
Why?
| | Cytomegalovirus Infections | 1 | 2025 | 192 | 0.050 |
Why?
| | Area Under Curve | 1 | 2024 | 314 | 0.050 |
Why?
| | Gadolinium | 1 | 2023 | 82 | 0.050 |
Why?
| | Myocytes, Cardiac | 1 | 2007 | 526 | 0.050 |
Why?
| | Calcineurin Inhibitors | 1 | 2022 | 72 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2025 | 1066 | 0.050 |
Why?
| | Cause of Death | 2 | 2015 | 434 | 0.050 |
Why?
| | Quality of Life | 2 | 2023 | 2892 | 0.040 |
Why?
| | Aged | 4 | 2017 | 23961 | 0.040 |
Why?
| | Biomechanical Phenomena | 1 | 2024 | 810 | 0.040 |
Why?
| | Living Donors | 1 | 2023 | 295 | 0.040 |
Why?
| | Utah | 2 | 2012 | 69 | 0.040 |
Why?
| | Age of Onset | 1 | 2022 | 518 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2022 | 665 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 2019 | 45 | 0.040 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2019 | 23 | 0.040 |
Why?
| | Logistic Models | 1 | 2024 | 2074 | 0.040 |
Why?
| | Genes, ras | 1 | 2019 | 97 | 0.040 |
Why?
| | Immunity, Cellular | 2 | 2012 | 268 | 0.040 |
Why?
| | ras Proteins | 1 | 2019 | 153 | 0.040 |
Why?
| | Postoperative Period | 1 | 2019 | 342 | 0.040 |
Why?
| | Machine Learning | 1 | 2023 | 493 | 0.040 |
Why?
| | Prevalence | 2 | 2015 | 2734 | 0.040 |
Why?
| | Adenoidectomy | 1 | 2017 | 72 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2844 | 0.030 |
Why?
| | Brazil | 1 | 2017 | 167 | 0.030 |
Why?
| | Sample Size | 1 | 2017 | 125 | 0.030 |
Why?
| | Education, Medical, Continuing | 1 | 2017 | 127 | 0.030 |
Why?
| | Genetic Variation | 1 | 2022 | 991 | 0.030 |
Why?
| | United Kingdom | 1 | 2017 | 318 | 0.030 |
Why?
| | Tonsillectomy | 1 | 2017 | 89 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2021 | 655 | 0.030 |
Why?
| | Kidney | 1 | 2023 | 1468 | 0.030 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 273 | 0.030 |
Why?
| | Gadolinium DTPA | 1 | 2016 | 70 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 786 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1430 | 0.030 |
Why?
| | Orthopedic Procedures | 1 | 2017 | 216 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2018 | 1316 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2022 | 1774 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2025 | 1809 | 0.030 |
Why?
| | Lower Extremity Deformities, Congenital | 1 | 2014 | 1 | 0.030 |
Why?
| | Upper Extremity Deformities, Congenital | 1 | 2014 | 1 | 0.030 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2014 | 30 | 0.030 |
Why?
| | Comparative Genomic Hybridization | 1 | 2014 | 30 | 0.030 |
Why?
| | Breast Diseases | 1 | 2014 | 22 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1622 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 62 | 0.030 |
Why?
| | Ulna | 1 | 2014 | 27 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 554 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2022 | 3556 | 0.030 |
Why?
| | Aortic Valve Insufficiency | 1 | 2014 | 47 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1007 | 0.030 |
Why?
| | Drug Therapy | 1 | 2014 | 85 | 0.030 |
Why?
| | Preoperative Period | 1 | 2014 | 129 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1639 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 399 | 0.030 |
Why?
| | Heart Septal Defects, Atrial | 1 | 2014 | 54 | 0.030 |
Why?
| | Radiography | 1 | 2015 | 822 | 0.020 |
Why?
| | Population Dynamics | 1 | 2013 | 151 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2014 | 377 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2013 | 307 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2012 | 88 | 0.020 |
Why?
| | Cardiac Surgical Procedures | 1 | 2017 | 530 | 0.020 |
Why?
| | Coronary Angiography | 1 | 2014 | 317 | 0.020 |
Why?
| | Brain Death | 1 | 2011 | 46 | 0.020 |
Why?
| | Coronary Circulation | 1 | 2012 | 143 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 806 | 0.020 |
Why?
| | Complement C4b | 1 | 2010 | 9 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1477 | 0.020 |
Why?
| | Necrosis | 1 | 2011 | 246 | 0.020 |
Why?
| | Complement C3d | 1 | 2010 | 67 | 0.020 |
Why?
| | Diastole | 1 | 2010 | 149 | 0.020 |
Why?
| | Systole | 1 | 2010 | 189 | 0.020 |
Why?
| | Ultrasonography | 1 | 2014 | 759 | 0.020 |
Why?
| | Fibrin | 1 | 2010 | 81 | 0.020 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 270 | 0.020 |
Why?
| | Chronic Disease | 1 | 2016 | 1793 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2010 | 228 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1171 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2017 | 3284 | 0.020 |
Why?
| | Isoantibodies | 1 | 2008 | 60 | 0.020 |
Why?
| | Ischemia | 1 | 2011 | 409 | 0.020 |
Why?
| | Oxygen | 1 | 2013 | 931 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2012 | 752 | 0.020 |
Why?
| | Gap Junctions | 1 | 2007 | 59 | 0.020 |
Why?
| | Cytoskeletal Proteins | 1 | 2007 | 158 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2010 | 706 | 0.020 |
Why?
| | Regression Analysis | 1 | 2008 | 1024 | 0.020 |
Why?
| | Dogs | 1 | 2007 | 413 | 0.020 |
Why?
| | Disease Progression | 1 | 2013 | 2757 | 0.010 |
Why?
| | Blotting, Western | 1 | 2007 | 1226 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2007 | 812 | 0.010 |
Why?
| | Stroke | 1 | 2012 | 1120 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3566 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2007 | 4295 | 0.010 |
Why?
| | Animals | 1 | 2007 | 36940 | 0.000 |
Why?
|
|
Everitt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|